FDA Claims Success with PROs as Trial Endpoints

12.12.17

You may have read our white paper on the new dataset: patient-reported outcomes (PROS), but did you know that the FDA is now on board?

“PROs are important because the value of any medical intervention ultimately lies in improving the patient’s sense of well-being. Also, they have the practical advantage of measuring effects that clinicians can’t readily evaluate, such as pain.”

Read more here.